Antisense Pharma GmbH The company is a biopharmaceutical company committed to researching, developing and marketing innovative medicines. Our drugs enable targeted treatment of aggressive tumor diseases. Our main objective is to extend the life expectancy of patients considerably and, at the same time, improve their quality of life. Founded in 1998, the company is located at the Biopark in Regensburg – one of the most successful biotechnology centers in Germany. Our executive management has many years of entrepreneurial experience, expertise in the biopharmaceutical sector and a sound medical and scientific background. It is supported by a dedicated team with broad experience in the development, approval and marketing of new medicines. The drugs currently in development belong to the ‘targeted therapies’, i.e. they block the synthesis of key proteins, which are responsible for the onset and progression of especially aggressive tumor diseases. These drugs do not alter the genome. With this novel approach, we treat the cause of the disease and not merely its symptoms. The company employs exclusively the platform technology .R.A.D.A.R.® to identify the best antisense molecules as drug candidates. The company has an extensive international patent portfolio with over 100 issued patents. By focusing on the most promising drug candidates, the company was able to initiate the first clinical study of its first product already two years after the company’s founding. We excel at implementing ideas into patents and fast product development. Our lead product, trabedersen, is our most advanced drug in terms of clinical development. It is now in the final phase of clinical testing before market approval for high grade glioma (malignant brain tumor). The company is an international leader in the development of antisense drugs.